NEW YORK, Sept. 20 – Tranzyme of Birmingham, Ala., and Active Pass Pharmaceuticals of Vancouver, said Thursday they had agreed to combine their technologies in an effort to study gene expression and bolster their drug discovery programs.
Registering provides access to this and other free content.
Already have an account?Login Now.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.